« Return to News | CROs/Service Providers

Catalent Pharma Solutions expands manufacturing facility

Friday, June 14, 2013 01:41 PM

Catalent Pharma Solutions, a global drug delivery technology and advanced supply solutions company, has announced an expansion of its controlled release drug manufacturing facility in Winchester, Ky. Catalent will invest nearly $35 million to expand the 100,000-square-foot facility by almost 80,000 square feet of modern manufacturing space, and will add as many as 90 new employees.

Opened in 1992, Catalent's Winchester facility focuses on advanced oral controlled-release drug formulation and manufacturing, and has launched over 100 products for Catalent's pharmaceutical and consumer health customers.

"As with Winchester, Catalent continues to invest to meet the most critical needs of the industry, including recently announced inhalation facility expansion in North Carolina, our recently completed biologics expansion in Wisconsin and our two new ventures in China, which will focus on softgel technologies and clinical trial supplies," said John Chiminski, Catalent president and chief executive officer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.